These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 1660689)

  • 21. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas.
    Robanus-Maandag EC; Bosch CA; Kristel PM; Hart AA; Faneyte IF; Nederlof PM; Peterse JL; van de Vijver MJ
    J Pathol; 2003 Sep; 201(1):75-82. PubMed ID: 12950019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-myc protein expression in human breast carcinoma: prognostic implications.
    Mizukami Y; Nonomura A; Takizawa T; Noguchi M; Michigishi T; Nakamura S; Ishizaki T
    Anticancer Res; 1995; 15(6B):2899-905. PubMed ID: 8669886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Growth factors as biological markers of malignancy].
    Tahara E; Yokozaki H
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):1102-8. PubMed ID: 3260465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
    Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
    Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationships between epidermal growth factor receptor (EGF-R) and other predictors of prognosis in breast carcinomas. An immunohistochemical study.
    Martinazzi M; Crivelli F; Zampatti C; Martinazzi S
    Pathologica; 1993; 85(1100):637-44. PubMed ID: 8170712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer.
    Miyamoto H; Harada M; Isobe H; Akita HD; Haneda H; Yamaguchi E; Kuzumaki N; Kawakami Y
    Cancer Res; 1991 Dec; 51(23 Pt 1):6346-50. PubMed ID: 1657384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implication of the ras and myc oncoproteins in the pathogenesis of mycosis fungoides.
    Tosca A; Linardopoulos S; Malliri A; Hatziolou E; Nicolaidou A; Spandidos DA
    Anticancer Res; 1991; 11(4):1433-8. PubMed ID: 1746900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of epidermal growth factor receptor by activated H-ras and V-myc oncogenes in mouse Balb/3T3 cells: possible roles of AP-1.
    Okimoto T; Kohno K; Kuwano M; Gopas J; Kung HF; Ono M
    Oncogene; 1996 Apr; 12(8):1625-33. PubMed ID: 8622882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High levels of c-myc protein in human breast tumours determined by a sensitive ELISA technique.
    Spandidos DA; Field JK; Agnantis NJ; Evan GI; Moore JP
    Anticancer Res; 1989; 9(4):821-6. PubMed ID: 2683996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene.
    Liu J; Spence MJ; Wallace PM; Forcier K; Hellström I; Vestal RE
    Cell Growth Differ; 1997 Jun; 8(6):667-76. PubMed ID: 9186000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours.
    Kumar S; Hand PH; Marsden HB; Kumar P; Thor A
    Anticancer Res; 1991; 11(4):1657-62. PubMed ID: 1660693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The expression of c-myc and c-N-ras in human cirrhotic livers, hepatocellular carcinomas and liver tissue surrounding the tumors.
    Zhang XK; Huang DP; Qiu DK; Chiu JF
    Oncogene; 1990 Jun; 5(6):909-14. PubMed ID: 2163054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical detection of ras p21 and c-myc p62 in colonic adenomas and carcinomas.
    Agnantis NJ; Apostolikas N; Sficas C; Zolota V; Spandidos DA
    Hepatogastroenterology; 1991 Jun; 38(3):239-42. PubMed ID: 1937363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
    Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
    Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer.
    Hainsworth PJ; Henderson MA; Stillwell RG; Bennett RC
    Eur J Surg Oncol; 1991 Feb; 17(1):9-15. PubMed ID: 1671658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma.
    Pavelic ZP; Pavelic L; Lower EE; Gapany M; Gapany S; Barker EA; Preisler HD
    Cancer Res; 1992 May; 52(9):2597-602. PubMed ID: 1348967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of heat shock protein 70 and c-myc protein in human breast cancer: an immunohistochemical study.
    Tauchi K; Tsutsumi Y; Hori S; Yoshimura S; Osamura RY; Watanabe K
    Jpn J Clin Oncol; 1991 Aug; 21(4):256-63. PubMed ID: 1658414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular genetics of malignant insulinoma.
    Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
    Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
    de Candia P; Akram M; Benezra R; Brogi E
    Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.